Board of Directors
Mr. Kelley has over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He currently serves on the Board of Directors of Adjuvance Technologies, ID Biologics, Meissa Vaccines, Public Health Vaccines, and publicly held Halozyme Therapeutics. Previously, Mr. Kelley was co-founder, CEO and Chairman of PaxVax. Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners and Institutional Venture Partners (IVP) and has made over 40 biotechnology and medical startup investments. Mr. Kelley was a White House Presidential Executive Fellow from 2016-2017 as well as an Advanced Leadership Initiative (ALI) Fellow at Harvard University from 2015-2016. He earned an M.B.A. from Stanford University and a B.A. in biochemical sciences from Harvard University.